Literature DB >> 175902

The carbohydrate composition of human apo low density lipoprotein from normal and type II hyperlipoproteinemic subjects.

P Lee, W C Breckenridge.   

Abstract

The carbohydrate composition of the apoprotein from low density lipoprotein (LDL) of normal (average LDL cholesterol, 122 mg/100 ml) and type II hyperlipoproteinemic (average LDL cholesterol, 236 mg/100 ml) males was studied using gas-liquid chromatographic analysis of the methul glycoside derivatives. All samples containing detectable sinking pre-beta-lipoprotein were excluded from the study. The apo LDL from both groups of subjects contained mannose, galactose, N-acetyl-glucosamine and N-acetylneuraminic acid. Glucose and fucose were not found while trace quantities of galactosamine were detected. Although the quantities of galactose and N-acetylglycosamine were the same in the two groups, lower quantities of mannose (p less than or equal to 0.01) and N-acetylneuraminic acid (p less than or equal to 0.05) were found in the type II patients as opposed to normal subjects.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 175902     DOI: 10.1139/o76-007

Source DB:  PubMed          Journal:  Can J Biochem        ISSN: 0008-4018


  4 in total

1.  Analysis of the apolipoprotein B gene and messenger ribonucleic acid in abetalipoproteinemia.

Authors:  K J Lackner; J C Monge; R E Gregg; J M Hoeg; T J Triche; S W Law; H B Brewer
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

2.  A comparison of composition and fluidity of multiple sclerosis and normal myelin.

Authors:  J M Boggs; M A Moscarello
Journal:  Neurochem Res       Date:  1980-03       Impact factor: 3.996

3.  Analysis of cDNA clones encoding the entire B-26 region of human apolipoprotein B.

Authors:  A A Protter; D A Hardman; K Y Sato; J W Schilling; M Yamanaka; Y J Hort; K A Hjerrild; G C Chen; J P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Carbohydrate composition of circulating multiple-modified low-density lipoprotein.

Authors:  Emile R Zakiev; Igor A Sobenin; Vasily N Sukhorukov; Veronika A Myasoedova; Ekaterina A Ivanova; Alexander N Orekhov
Journal:  Vasc Health Risk Manag       Date:  2016-10-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.